Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis. Since ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Researchers have found that an FDA-approved arthritis drug suppresses seizures and improves memory, offering new hope for a ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in ...

Approval is for use in myelofibrosis patients with moderate to severe anaemia who are JAK-naive or previously treated with ...

Janus kinase inhibitors (JAKis ... Because these drugs specifically block cellular signalling pathways that are responsible for maintaining inflammatory responses, JAKi have been researched ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the ...

Janus kinase (JAK) inhibitors have revolutionized ... of interleukin-7 and the thymic stromal lymphopoietin (TSLP) pathway, potentially bringing a novel approach to the control of AA, according ...